AG1 Hit $600M in Revenue — Here Is What the Data Actually Shows

AG1 — formerly Athletic Greens — is the most studied brand in the premium supplement category. Every DTC operator knows the story: one product, one SKU, a podcast advertising juggernaut, and a subscription model that turned greens powder into a $600M business. The question that nobody has cleanly answered: how does this business actually work, and how durable is it?

We have been modeling AG1 since Pulsse launched. Here is what the data shows.

The Revenue Picture

AG1's $600M figure is our estimate for their 2025 annual revenue, derived from three signals: their publicly disclosed subscriber count (approximately 420,000 active subscribers as of Q3 2025), their average subscription revenue per subscriber (approximately $109/month based on their published pricing), and an adjustment for one-time purchases and retail channel revenue.

The DTC subscription concentration is striking: approximately 91% of AG1's revenue comes from their own subscription channel. This is intentional and makes AG1 almost unique in consumer goods — they have maintained retail distribution as a deliberately small part of their business, preferring to own the customer relationship entirely.

The Subscriber Economics

The heart of the AG1 business model is subscriber retention. At $109/month, AG1 is one of the most expensive supplement subscriptions on the market. Maintaining that at scale requires extraordinary retention — a single point of churn improvement is worth approximately $55M in annual recurring revenue at their current subscriber count.

We model AG1's monthly churn at approximately 5.5–6.5%, which implies a median subscriber lifetime of 15–18 months and an average LTV in the range of $1,635–$1,962. Against an estimated CAC that has historically run $80–$120 per acquired subscriber (through podcast advertising deals), this is exceptional economics — an LTV:CAC ratio above 15x at the midpoint.

AG1 is not a supplement company with good marketing. It is a subscriber business that chose supplements as the vehicle. That distinction matters enormously for how you analyze and value it.

Why CAC Is Actually Decreasing

The conventional wisdom is that DTC brands face rising CAC over time as they exhaust their core audience and move into less efficient channels. AG1 appears to be bucking this trend, and the reason is structural rather than tactical.

AG1's podcast advertising portfolio has been running long enough that the cumulative reach of the same channels is actually expanding — podcast listenership has grown 35% in the past two years across the health and wellness shows where AG1 advertises. They are reaching new listeners on the same shows, at the same cost per spot, as the audience compounds.

Additionally, AG1 has invested heavily in influencer and affiliate programs that now drive meaningful subscriber acquisition at near-zero marginal cost. We estimate that approximately 18–22% of new AG1 subscribers in 2025 came through affiliate or referral channels — a figure that effectively blends down the CAC for paid acquisition.

The Risks

AG1 is not without vulnerability. Their concentration in DTC subscription means they are exposed to any platform-level change that affects their payment processing, email marketing, or affiliate network. They have minimal retail presence as a hedge — a strategic choice that gives them margin control but limits the "floor" on revenue if DTC dynamics shift.

The competitive landscape is also intensifying. Every supplement brand is watching AG1's playbook and launching their own all-in-one greens formulas. Momentous, Huel, and a dozen smaller brands are all competing for the "one comprehensive supplement" customer. AG1's moat is brand — they have years of trust-building through their podcast network — but brand moats erode faster than people expect when the category gets crowded.

At $600M in revenue, AG1 is a standalone business of meaningful scale. Whether they pursue an IPO, a strategic acquisition (Nestlé and Unilever are the obvious suspects), or continue to compound as a private company is the most interesting strategic question in the premium supplement category right now.